Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model

Autor: Susan Reed, Adriana Cervantes-Medina, Amy Lwin, Lindsay Czajkowski, Luz Angela Rosas, Rani Athota, Monica Gouzoulis, Jerald C. Sadoff, Sally Hunsberger, Matthew J. Memoli, Holly Ann Baus, Alison Han, Yongli Xiao, Keith Lumbard, Jeffery K. Taubenberger

Publikováno v: Clin Infect Dis

Background It is imperative to identify new targets for improved vaccines and therapeutics against influenza. One such target is the relatively conserved stalk region of the influenza A hemagglutinin (HA) surface protein. Methods We conducted a rando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ce7dcbb6cb4bf099774f1b57ee7161
https://doi.org/10.1093/cid/ciaa1725

RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults

Autor: Gert Scheper, Macaya Douoguih, Frank Struyf, Mathieu Le Gars, Vicky Cárdenas, Hanneke Schuitemaker, Jenny Hendriks, Javier Ruiz Guiñazú, Nathalie Vaissiere, Carla Truyers, Jerald C. Sadoff

Publikováno v: Respiratory infections and bronchiectasis.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5323a1054539d03632c8bed5c4236720
https://doi.org/10.1183/13993003.congress-2021.pa489

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

Autor: Johan Van Hoof, Jinyan Liu, Macaya Douoguih, Jerald C. Sadoff, Frank Struyf, Makda S. Gebre, Jingyou Yu, Anne Marit de Groot, Mathieu Le Gars, Katherine McMahan, Abishek Chandrashekar, Shivani A. Patel, Aiquan Chang, Hanneke Schuitemaker, Dan H. Barouch, Kathryn E. Stephenson, Dirk Heerwegh

Publikováno v: The New England Journal of Medicine

Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported1-3. We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e6ebc9b20b64e6752e0a9403099c3c
https://doi.org/10.1101/2021.07.05.21259918

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer

Autor: Macaya Douoguih, Jerald C. Sadoff, Kourtney Davis

Publikováno v: The New England Journal of Medicine

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Manufacturer’s Response The manufacturer of the Ad26.COV2.S vaccine against Covid-19 comments on recent reports of thrombosis, including ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5df577c51afe5845047b221ab73dfc0
http://europepmc.org/articles/PMC8117965

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Autor: Hanneke Schuitemaker, Jerald C. Sadoff, Gert Scheper, Jeroen Stoop, Emmanuel Cormier, Pierre Van Damme, Isabel Leroux-Roels, Johan Van Hoof, Anne Marit de Groot, Wim Van Damme, Frank Struyf, Sarah Tete, Carla Truyers, Mathieu Le Gars, Jenny Hendriks, William T. Smith, Murray Kimmel, Dirk Heerwegh, Kristen W. Cohen, Georgi Shukarev, Jan de Hoon, M Juliana McElrath, Macaya Douoguih, Dan H. Barouch, Stephen C De Rosa, Pieter-Jan Berghmans, Kathryn E. Stephenson

Publikováno v: The New England Journal of Medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine

BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c40706ef16b35abb562edeeb244f6a29
https://pubmed.ncbi.nlm.nih.gov/33440088